- Report
- January 2024
- 112 Pages
Global
From €3500EUR$4,241USD£3,127GBP
- Report
- January 2024
- 73 Pages
Global
From €3500EUR$4,241USD£3,127GBP
- Report
- January 2024
- 113 Pages
Global
From €3500EUR$4,241USD£3,127GBP
- Report
- May 2022
- 106 Pages
Global
From €3500EUR$4,241USD£3,127GBP
From €114EUR$129USD£98GBP
- Book
- June 2018
- 368 Pages
- Book
- November 2015
- 776 Pages
- Book
- August 2014
- 240 Pages
- Book
- January 2018
- 272 Pages
- Book
- April 2014
- 552 Pages
- Book
- April 2013
- 320 Pages
- Book
- September 2010
- 418 Pages
- Book
- April 2009
- 528 Pages
- Book
- April 2013
- 778 Pages

The Embryonic Stem Cell (ESC) market is a subset of the larger stem cell market. ESCs are derived from embryos and are pluripotent, meaning they can differentiate into any cell type in the body. They are used in research to study the development of cells and tissues, and in regenerative medicine to replace damaged or diseased cells. ESCs are also used in drug discovery and development, as they can be used to test the safety and efficacy of new drugs.
The ESC market is highly regulated, as the use of embryos is controversial. Regulations vary by country, and some countries have banned the use of ESCs altogether. Despite this, the ESC market is growing, driven by advances in stem cell research and the potential for regenerative medicine.
Companies in the ESC market include Cellular Dynamics International, Pluristem Therapeutics, and Stem Cell Therapeutics. These companies are involved in the research, development, and commercialization of ESCs for therapeutic and research applications. Show Less Read more